Pyridine-3-carboxylate Compounds Selective Cav1.2 Activation

The patent applies local quality by designing compounds that selectively activate Cav1.2 channels in neuronal tissue while minimizing activation in cardiovascular tissue. The pyridine-3-carboxylate structure with specific substituents (R1=C1-6 alkyl/haloalkyl, R2=H/halo, R3=C1-6 alkyl/C3-8 cycloalkyl) creates differential binding affinity, allowing the drug to preferentially target neuronal Cav1.2 channels over cardiac channels, thus achieving local therapeutic effect while reducing systemic cardiovascular side effects

The patent employs parameter changes by optimizing the chemical structure parameters of calcium channel activators. By systematically varying substituent groups on the pyridine-3-carboxylate core (different alkyl chains, halogen positions, cycloalkyl variations), the invention tunes the pharmacological parameters including potency, selectivity, and tissue distribution to achieve enhanced neuronal efficacy with reduced cardiovascular toxicity

The patent systematically optimizes molecular parameters including substituent type (alkyl vs haloalkyl), substituent position (R1, R2, R3 locations on the pyridine ring), and molecular size (C1-6 vs C1-4 alkyl variations) to enhance both potency and patient benefit. This structured parameter exploration leads to compounds with improved pharmacokinetic properties and enhanced therapeutic efficacy compared to existing small molecules

The patent creates composite molecular structures by combining the pyridine-3-carboxylate core with various functional groups (alkyl chains, halogen atoms, cycloalkyl rings) to produce a series of compounds with differentiated properties. This composite approach allows selection of optimal combinations that maximize therapeutic benefit while minimizing side effects